Final Development Stage For Prolia Reflects Amgen's Eye On Advertising
This article was originally published in The Pink Sheet Daily
Executive Summary
Biotech's roll-out of clinical data on the RANK ligand inhibitor no longer is studies that supported the initial application but studies focused on particular claims or comparative advantages that will improve Prolia's commercial outlook.
You may also be interested in...
Inflamed Language: FDA Sends Harsh Warning Letter To Allergan For Acne Drug
Allergan gets slammed for Aczone Gel promotional claims that FDA says are backed by data "not even nominally statistically significant."
Amgen's Mixed Advisory Committee Votes On Prolia Still Offer A Good Start
The Reproductive Health Drugs Advisory Committee backs Prolia's use to treat osteoporosis in postmenopausal women and bone loss in men undergoing hormone ablation therapy for prostate cancer - though not the largest indication of osteoporosis prevention as well as a REMS.
Denosumab Approval Is “Highly Likely,”– Interview With Amgen’s Perlmutter
In a Jan. 26 interview, Amgen Executive VP for Research and Development Roger Perlmutter talks about denosumab, follow-on biologics and how Amgen is avoiding the size-related innovation drought that many big pharma companies now face.